GYRE THERAPEUTICS, INC. (GYRE)

Every figure below is the company's own, as filed. Nothing is estimated and nothing is smoothed — a period the filing does not support is left blank rather than drawn. Quarters are the company's own, counted from its financial year ending 12-31. Amounts in USD.

Revenue TTM

0 50M 100M 150M Q4 '10: 85.7M Q1 '11: 105.2M Q2 '11: 105M Q3 '11: 102.2M Q4 '11: 97.6M Q1 '12: 81.5M Q2 '12: 94.4M Q3 '12: 76.2M Q4 '12: 57.9M Q1 '13: 38.5M Q2 '13: 4.9M Q3 '13: 4.1M Q4 '13: 3.6M Q1 '14: 180K Q2 '14: 216K Q3 '14: 241K Q4 '14: 275K Q1 '15: 248K Q2 '15: 212K Q4 '17: 1M Q1 '18: 753K Q2 '18: 642K Q3 '18: 324K Q4 '18: 6K Q4 '20: 20.9M Q1 '21: 6M Q2 '21: 5.5M Q3 '21: 6.9M Q4 '21: 7.3M Q1 '22: 6.7M Q4 '23: 113.5M Q1 '24: 115.7M Q2 '24: 111.6M Q3 '24: 105M Q4 '24: 105.8M Q1 '25: 100.6M Q2 '25: 105.2M Q3 '25: 110.2M Q4 '25: 119.6M Q1 '26: 120M Q2 '26: 119.4M Q4 '11 Q2 '13 Q4 '14 Q3 '18 Q4 '21 Q4 '24 Q2 '26

Gross Profit TTM

0 40M 80M 120M Q4 '23: 108.8M Q1 '24: 111.2M Q2 '24: 107.4M Q3 '24: 101.1M Q4 '24: 101.9M Q1 '25: 96.8M Q2 '25: 98M Q3 '25: 102.4M Q4 '23 Q1 '24 Q2 '24 Q3 '24 Q4 '24 Q1 '25 Q2 '25 Q3 '25

Operating Income TTM

-90M -60M -30M 0 30M 60M 90M Q4 '11: -9.7M Q1 '12: -20.1M Q2 '12: -3.3M Q3 '12: -2M Q4 '12: -8.1M Q1 '13: -18.4M Q2 '13: -45.1M Q3 '13: -50.2M Q4 '13: -47.2M Q1 '14: -50.7M Q2 '14: -46.4M Q1 '15: -8.7M Q2 '15: -8.7M Q3 '15: -10.9M Q4 '15: -13.8M Q1 '16: -15.3M Q2 '16: -18.1M Q3 '16: -19.9M Q4 '16: -20.4M Q1 '17: -20M Q2 '17: -21M Q3 '17: -21.2M Q4 '17: -21.8M Q1 '18: -24.3M Q2 '18: -25.5M Q3 '18: -28M Q4 '18: -33.8M Q1 '19: -42.9M Q2 '19: -50.1M Q3 '19: -55M Q4 '19: -57.3M Q1 '20: -46.6M Q2 '20: -49.6M Q3 '20: -52.5M Q4 '20: -57.4M Q1 '21: -74.7M Q2 '21: -77.3M Q3 '21: -86.4M Q4 '21: -87.9M Q1 '22: -80.2M Q2 '22: -8.7M Q3 '22: 11.3M Q4 '22: 9.2M Q1 '23: 30.6M Q2 '23: -16M Q3 '23: 1.9M Q4 '23: -67.2M Q1 '24: -65.8M Q2 '24: -67.6M Q3 '24: -76.1M Q4 '24: 16.2M Q1 '25: 10.4M Q2 '25: 4.9M Q3 '25: 7.6M Q4 '25: 7.1M Q1 '26: -4.6M Q2 '26: -16.7M Q4 '11 Q4 '13 Q2 '16 Q2 '18 Q2 '20 Q2 '22 Q2 '24 Q2 '26

Net Income TTM

-90M -60M -30M 0 30M 60M 90M Q4 '11: -8.5M Q1 '12: -18.9M Q2 '12: -2.1M Q3 '12: -933K Q4 '12: -7M Q1 '13: -17.3M Q2 '13: -44.2M Q3 '13: -49.2M Q4 '13: -46.7M Q1 '14: -53.6M Q2 '14: -49.4M Q1 '15: -7.7M Q2 '15: -7.4M Q3 '15: -10.9M Q4 '15: -14.8M Q1 '16: -15.5M Q2 '16: -18.6M Q3 '16: -18.3M Q4 '16: -16.9M Q1 '17: -17.5M Q2 '17: -18.5M Q3 '17: -19.6M Q4 '17: -21.6M Q1 '18: -22.5M Q2 '18: -23.1M Q3 '18: -25M Q4 '18: -30.1M Q1 '19: -40.1M Q2 '19: -47.4M Q3 '19: -52.4M Q4 '19: -55.2M Q1 '20: -44.1M Q2 '20: -47.6M Q3 '20: -50.9M Q4 '20: -56.2M Q1 '21: -74.6M Q2 '21: -77.3M Q3 '21: -86.5M Q4 '21: -87.9M Q1 '22: -80M Q2 '22: -8.5M Q3 '22: 11.9M Q4 '22: 4.3M Q1 '23: 23.1M Q2 '23: -24.8M Q3 '23: -12.4M Q4 '23: -66.2M Q1 '24: -60.5M Q2 '24: -59.7M Q3 '24: -64.4M Q4 '24: 17.9M Q1 '25: 12.9M Q2 '25: 6.2M Q3 '25: 9.2M Q4 '25: 9.9M Q1 '26: -13.6M Q2 '26: -25.7M Q4 '11 Q4 '13 Q2 '16 Q2 '18 Q2 '20 Q2 '22 Q2 '24 Q2 '26

Cost of Revenue TTM

0 2.5M 5M 7.5M Q4 '23: 4.6M Q1 '24: 4.5M Q2 '24: 4.2M Q3 '24: 4M Q4 '24: 3.9M Q1 '25: 3.8M Q2 '25: 4.2M Q3 '25: 4.8M Q4 '25: 5.4M Q1 '26: 5.7M Q2 '26: 6.8M Q4 '23 Q2 '24 Q4 '24 Q2 '25 Q4 '25 Q2 '26

Operating Cash Flow TTM

-90M -60M -30M 0 30M 60M 90M Q4 '11: -83.7M Q1 '12: -86.6M Q2 '12: -80.8M Q3 '12: -73.2M Q4 '12: -64.2M Q1 '13: -48.7M Q2 '13: -41.7M Q3 '13: -41M Q4 '13: -40.6M Q1 '14: -46.1M Q2 '14: -44.6M Q3 '14: -35.6M Q4 '14: -6.4M Q1 '15: 5.5M Q2 '15: 13M Q3 '15: 4M Q4 '15: -19.1M Q1 '16: -20.9M Q2 '16: -23.2M Q3 '16: -18.6M Q4 '16: -18.5M Q1 '17: -18M Q2 '17: -18.8M Q3 '17: -18.6M Q4 '17: -19.9M Q1 '18: -20.8M Q2 '18: -23.8M Q3 '18: -25.9M Q4 '18: -28.6M Q1 '19: -38.4M Q2 '19: -42.5M Q3 '19: -44.5M Q4 '19: -43.6M Q1 '20: -33.4M Q2 '20: -37.1M Q3 '20: -41M Q4 '20: -55M Q1 '21: -74.6M Q2 '21: -79.6M Q3 '21: -88.2M Q4 '21: -83.8M Q1 '22: -71.4M Q2 '22: -63.6M Q3 '22: -49.3M Q4 '22: 10.7M Q1 '23: 33.1M Q2 '23: 50M Q3 '23: 64.8M Q4 '23: 25.9M Q1 '24: 18.4M Q2 '24: 8.3M Q3 '24: 2.5M Q4 '24: -3.6M Q1 '25: -6.7M Q2 '25: -8.6M Q3 '25: 3.9M Q4 '25: 1M Q1 '26: 4.3M Q2 '26: -4.9M Q2 '12 Q2 '14 Q2 '16 Q2 '18 Q2 '20 Q2 '22 Q2 '24 Q2 '26

Free Cash Flow TTM

-90M -60M -30M 0 30M 60M 90M Q4 '11: -85.1M Q1 '12: -87.5M Q2 '12: -81.4M Q3 '12: -73.6M Q4 '12: -64.6M Q1 '13: -49M Q2 '13: -42M Q3 '13: -41.3M Q4 '13: -40.7M Q3 '16: -19.1M Q4 '16: -18.9M Q1 '17: -18.4M Q2 '17: -18.9M Q3 '17: -18.7M Q4 '17: -20M Q1 '18: -21M Q2 '18: -24M Q3 '18: -26.1M Q4 '18: -28.9M Q1 '19: -38.6M Q2 '19: -42.7M Q3 '19: -44.8M Q4 '19: -43.7M Q1 '20: -33.5M Q2 '20: -37.1M Q3 '20: -41.2M Q4 '23: 17.4M Q1 '24: 11.4M Q2 '24: 2.3M Q3 '24: -2.2M Q4 '24: -6M Q1 '25: -8.9M Q2 '25: -9.7M Q3 '25: 2.9M Q4 '25: -180K Q1 '26: 3.1M Q2 '26: -6.1M Q1 '12 Q2 '13 Q1 '17 Q2 '18 Q3 '19 Q4 '23 Q1 '25 Q2 '26

Operating cash flow minus capital expenditure.

Shares Outstanding Quarterly

0 40M 80M 120M Q2 '10: 30.2M Q3 '10: 30.2M Q1 '11: 30.4M Q2 '11: 30.7M Q3 '11: 33.4M Q4 '11: 33.4M Q1 '12: 33.8M Q2 '12: 33.6M Q3 '12: 33.5M Q4 '12: 33.6M Q1 '13: 33.6M Q2 '13: 33.6M Q3 '13: 33.6M Q2 '21: 31.3M Q3 '21: 31.4M Q1 '22: 31.5M Q2 '22: 31.5M Q3 '22: 31.5M Q1 '23: 78.9M Q2 '23: 78.9M Q3 '23: 78.9M Q1 '24: 102.6M Q2 '24: 102.2M Q3 '24: 102.6M Q1 '25: 102M Q2 '25: 89.2M Q3 '25: 104M Q1 '26: 91.3M Q2 '26: 100.6M Q2 '10 Q3 '11 Q3 '12 Q3 '13 Q2 '22 Q3 '23 Q1 '25 Q2 '26

Weighted average diluted, as the filer reports it for each period. An average cannot be added across periods, so this one is always shown per period the filer tagged rather than as a trailing year.

EPS TTM

-30.00 -20.00 -10.00 0.00 10.00 20.00 30.00 Q4 '11: -0.22 Q1 '12: -0.56 Q2 '12: -0.06 Q3 '12: -0.03 Q4 '12: -0.21 Q1 '13: -0.52 Q2 '13: -1.32 Q3 '13: -1.46 Q4 '13: -27.29 Q1 '14: -27.49 Q2 '14: -27.36 Q1 '15: -15.48 Q2 '15: -19.86 Q3 '15: -16.71 Q4 '15: -13.65 Q1 '16: -10.69 Q2 '16: -12.42 Q3 '16: -17.53 Q4 '16: -21.73 Q1 '17: -21.59 Q2 '17: -17.79 Q3 '17: -13.09 Q4 '17: -9.40 Q1 '18: -5.39 Q2 '18: -3.40 Q3 '18: -2.70 Q4 '18: -2.67 Q1 '19: -3.37 Q2 '19: -3.98 Q3 '19: -4.40 Q4 '19: -4.60 Q1 '20: -3.62 Q2 '20: -3.43 Q3 '20: -3.10 Q4 '20: -2.85 Q1 '21: -3.36 Q2 '21: -3.04 Q3 '21: -3.11 Q4 '21: -2.87 Q1 '22: -2.54 Q2 '22: -0.26 Q3 '22: 0.38 Q4 '22: 0.03 Q1 '23: 0.52 Q2 '23: -1.10 Q3 '23: -0.89 Q4 '23: -1.41 Q2 '25: -0.02 Q3 '25: 0.00 Q4 '25: 0.02 Q1 '26: -0.08 Q2 '26: -0.17 Q2 '12 Q1 '14 Q2 '16 Q1 '18 Q4 '19 Q3 '21 Q2 '23 Q2 '26

The filer's own published earnings a share for each quarter, four quarters added up. The company page divides trailing net income by the share count instead, which lands within about 1% of this and is not the same sum, so the two are named differently rather than presented as one figure.